Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials

• Published in: Respiratory medicine Vol. 103; no. 12; pp. 1960 - 1968
• Main Authors: Sears, Malcolm R, Radner, Finn
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 01.12.2009; Elsevier; Elsevier Limited
• Subjects: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Asthma; Asthma - drug therapy; Asthma - mortality; Biological and medical sciences; Bronchodilator Agents - administration & dosage; Bronchodilator Agents - adverse effects; Budesonide - administration & dosage; Budesonide - adverse effects; Budesonide/formoterol maintenance and reliever therapy; Child; Chronic obstructive pulmonary disease, asthma; Clinical trials; Confidence intervals; Drug Combinations; Drug Therapy, Combination; Epidemiologic Methods; Ethanolamines - administration & dosage; Ethanolamines - adverse effects; Fatalities; Female; Formoterol Fumarate; Humans; Male; Medical sciences; Middle Aged; Mortality; Pneumology; Powders - administration & dosage; Powders - adverse effects; Pulmonary/Respiratory; Safety; Serious adverse events; Young Adult; Safety; Budesonide/formoterol maintenance and reliever therapy; Asthma; Serious adverse events; Lung disease; Budesonide; Respiratory disease; Maintenance; Treatment; Bronchus disease; Formoterol; Obstructive pulmonary disease; Pneumology

Summary Background The safety of long-acting β2 -agonists (LABAs) in asthma is debated. This study examined the safety of the inhaled corticosteroid (ICS)/LABA combination budesonide/formoterol dry powder inhaler used as maintenance and reliever therapy versus combination treatments based on guideli...